Tarsus completes acquisition of Alkeus, gaining worldwide rights to Phase 3 Stargardt candidate gildeuretinol (ALK-001) for its eye-care pipeline
https://finviz.com/stock?t=TARS&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.